At a glance
ClinicalIndex Comparison RecordN/ACompleted· 23 enrolled
Drug / intervention
EndoBarrier Linerdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Single-Center, Prospective, Open Label Efficacy Study, of the GI EndoBarrier™ Liner for the Treatment of Type 2 Diabetes
In Brief
A clinical study evaluating EndoBarrier Liner for Type 2 Diabetes. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The main objective of the study is to demonstrate the safety and efficacy of the Gastrointestinal (GI) EndoBarrier in the glycemic control of diabetes in subjects with Type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesBrazil
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartJun 2010
Primary CompletionNov 2011
Study CompletionNov 2012
TodayJul 2026
First PostedSep 29, 2009
Enrollment StartJun 1, 2010
Primary CompletionNov 1, 2011
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 16.8 years ago
Interventions
EndoBarrier Linerdevice
52 week treatment of EnoBarrier Liner